Diabetes Insipidus Induced by Combination of Short-acting Ocreotide and Lanreotide for Recurrent Carcinoid Crisis of Neuroendocrine Tumour
A Case Report
DOI:
https://doi.org/10.15605/jafes.036.02.09Keywords:
diabetes insipidus, octreotide, lanreotide, neuroendocrine tumors, malignant carcinoid syndromeAbstract
Somatostatin analogue is useful in carcinoid crisis for symptom control. Optimal dosing of somatostatin analogues for carcinoid symptoms is not known. This case highlighted management issues using combination short-acting octreotide infusion with long-acting lanreotide during carcinoid crisis. The patient had left lung neuroendocrine tumour metastasized to liver and bone, post left lobectomy. Due to extensive metastasis to liver causing recurrent carcinoid crisis, he required shorter interval long-acting lanreotide with continuous infusion of short-acting octreotide, which complicated with transient diabetes insipidus. Symptom resolved with discontinuation of treatment. Somatostatin analogues, especially in combination, may inhibit posterior pituitary resulting in diabetes insipidus. Prompt withdrawal of short-acting somatostatin analogue and initiation of desmopressin can reverse the complication. It is important to recognize this complication with combination of octreotide and lanreotide injections to avoid serious complications.
Downloads
References
Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–20. https://pubmed.ncbi.nlm.nih.gov/25646366. https://doi.org/10.1093/annonc/mdv041.
Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: A population-based study. Lancet Oncol. 2017;18(4):525–34. https://pubmed.ncbi.nlm.nih.gov/28238592. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066284. https://doi.org/10.1016/S1470-2045(17)30110-9.
Oliet SHR, Piet R, Poulain DA, et al. Glial modulation of synaptic transmission: Insights from the supraoptic nucleus of the hypothalamus. Glia. 2004;47(3):258–67. https://pubmed.ncbi.nlm.nih.gov/15252815. https://doi.org/10.1002/glia.20032.
Sherman TG, McKelvy JF, Watson SJ. Vasopressin mRNA regulation in individual hypothalamic nuclei: A Northern and in situ hybridization analysis. J Neurosci. 1986;6(6):1685–94. https://pubmed.ncbi.nlm.nih.gov/3712004. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6568715. https://doi.org/10.1523/JNEUROSCI.06-06-01685.1986.
Daftary SS, Boudaba C, Szabó K, et al. Noradrenergic excitation of magnocellular neurons in the rat hypothalamic paraventricular nucleus via intranuclear glutamatergic circuits. J Neurosci. 1998;18(24):10619–28. https://pubmed.ncbi.nlm.nih.gov/9852597. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6793374. https://doi.org/10.1523/JNEUROSCI.18-24-10619.1998.
Kabashima N, Shibuya I, Ibrahim N, et al. Inhibition of spontaneous EPSCs and IPSCs by presynaptic GABA(B) receptors on rat supraoptic magnocellular neurons. J Physiol. 1997;504(Pt 1):113–26. https://pubmed.ncbi.nlm.nih.gov/9350623. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1159941. https://doi.org/10.1111/j.1469-7793.1997.113bf.x.
Robertson GL. Diabetes insipidus. Endocrinol Metab Clin North Am. 1995;24(3): 549–72. https://pubmed.ncbi.nlm.nih.gov/8575409.
Renaud LP, Bourquet CW. Neurophysiology and neuropharmacology of hypothalamic magnocellular neurons secreting vasopressin and oxytocin. Progress in Neurobiology. 1991;36(2):131–69. https://pubmed.ncbi.nlm.nih.gov/1998074. https://doi.org/10.1016/0301-0082(91)90020-2.
Wang X, Tresham JJ, Congiu M, et al. Somatostatin centrally inhibits vasopressin secretion during haemorrhage. Brain Res. 1987;436(1):199–203. https://pubmed.ncbi.nlm.nih.gov/2891414. https://doi.org/10.1016/0006-8993(87)91577-0.
Ray C, Carney S, Morgan T, Gillies A. Somatostatin as a modulator of distal nephron water permeability. Clin Sci. 1993;84(4):455–60. https://pubmed.ncbi.nlm.nih.gov/8097684. https://doi.org/10.1042/cs0840455.
Ishida H, Lam AKY, pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. Crit Rev Oncol Hematol. 2019;145. https://pubmed.ncbi.nlm.nih.gov/31864179. https://doi.org/10.1016/j.critrevonc.2019.102835.
Janson ET, Oberg K. Long-term management of the carcinoid syndrome treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993;32(2):225–9. https://pubmed.ncbi.nlm.nih.gov/7686765. https://doi.org/10.3109/02841869309083916.
O’Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88(4):770–6. https://pubmed.ncbi.nlm.nih.gov/10679645. https://doi.org/10.1002/(sici)1097-0142(20000215)88:4<770::aid-cncr6>3.0.co;2-0.
Anthony L, Johnson D, Hande K, et al. Somatostatin analogue phase i trials in neuroendocrine neoplasms. Acta Oncol. 1993;32(2):217-23. https://pubmed.ncbi.nlm.nih.gov/7686764. https://doi.org/10.3109/02841869309083915.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Kian Guan Goh, Subashini Rajoo, Mohamed Badrulnizam Long Bidin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.
A written agreement shall be emailed to the requester should permission be granted.
